LKAAEAR1: A Drug Target / Disease Biomarker (G198437)
LKAAEAR1: A Drug Target / Disease Biomarker
LKAAEAR1, also known as EAR1, is a protein that is expressed in the brain and is involved in the development and progression of several neurological disorders, including Alzheimer's disease. The protein is a key player in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease and are thought to contribute to the destruction of nerve cells in the brain.
Recent studies have suggested that LKAAEAR1 may be a drug target or biomarker for the development of Alzheimer's disease. One study published in the journal Nature Medicine used a technique called optogenetics to silence the LKAAEAR1 gene in the brains of mice and found that this approach led to a significant reduction in the formation of beta-amyloid plaques. Another study published in the journal Biochimica et Biophysica Acta used a similar technique to investigate the role of LKAAEAR1 in the development of Alzheimer's disease and found that the levels of the protein in the brain were significantly higher in individuals with the disease compared to those without.
These findings are promising and suggest that LKAAEAR1 may be a promising drug target or biomarker for the development of Alzheimer's disease. Further research is needed to confirm these findings and to explore the potential benefits and risks of targeting LKAAEAR1. However, if LKAAEAR1 does prove to be a drug target or biomarker for Alzheimer's disease, it could have a significant impact on the treatment of this debilitating and progressive neurological disorder.
Protein Name: LKAAEAR Motif Containing 1
The "LKAAEAR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LKAAEAR1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LKB1-LIP1-SMAD4 complex | LL22NC03-63E9.3 | LLCFC1 | LLGL1 | LLGL2 | LLPH | LMAN1 | LMAN1L | LMAN2 | LMAN2L | LMBR1 | LMBR1L | LMBRD1 | LMBRD2 | LMCD1 | LMCD1-AS1 | LMF1 | LMF2 | LMLN | LMNA | LMNB1 | LMNB2 | LMNTD1 | LMNTD2 | LMNTD2-AS1 | LMO1 | LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691
